Integrin-αvβ3 is a Therapeutically Targetable Fundamental Factor in Medulloblastoma Tumorigenicity and Radioresistance.


Journal

Cancer research communications
ISSN: 2767-9764
Titre abrégé: Cancer Res Commun
Pays: United States
ID NLM: 9918281580506676

Informations de publication

Date de publication:
07 Dec 2023
Historique:
received: 12 07 2023
revised: 05 10 2023
accepted: 15 11 2023
pubmed: 27 11 2023
medline: 27 11 2023
entrez: 27 11 2023
Statut: ppublish

Résumé

Medulloblastoma is one of the most prevalent solid tumors found in children, occurring in the brain's posterior fossa. The standard treatment protocol involves maximal resection surgery followed by craniospinal irradiation and chemotherapy. Despite a long-term survival rate of 70%, wide disparities among patients have been observed. The identification of pertinent targets for both initial and recurrent medulloblastoma cases is imperative. Both primary and recurrent medulloblastoma are marked by their aggressive infiltration into surrounding brain tissue, robust angiogenesis, and resistance to radiotherapy. While the significant role of integrin-αvβ3 in driving these characteristics has been extensively documented in glioblastoma, its impact in the context of medulloblastoma remains largely unexplored. Integrin-αvβ3 was found to be expressed in a subset of patients with medulloblastoma. We investigated the role of integrin-αvβ3 using medulloblastoma-derived cell lines with β3-subunit depletion or overexpression both in vitro and in vivo settings. By generating radioresistant medulloblastoma cell lines, we uncovered an increased integrin-αvβ3 expression, which correlated with increased susceptibility to pharmacologic integrin-αvβ3 inhibition with cilengitide, a competitive ligand mimetic. Finally, we conducted single-photon emission computed tomography (SPECT)/MRI studies on orthotopic models using a radiolabeled integrin-αvβ3 ligand (99mTc-RAFT-RGD). This innovative approach presents the potential for a novel predictive imaging technique in the realm of medulloblastoma. Altogether, our findings lay the foundation for employing SPECT/MRI to identify a specific subset of patients with medulloblastoma eligible for integrin-αvβ3-directed therapies. This breakthrough offers a pathway toward more targeted and effective interventions in the treatment of medulloblastoma. This study demonstrates integrin-αvβ3's fundamental role in medulloblastoma tumorigenicity and radioresistance and the effect of its expression on cilengitide functional activity.

Identifiants

pubmed: 38009896
pii: 731300
doi: 10.1158/2767-9764.CRC-23-0298
pmc: PMC10702273
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2483-2496

Subventions

Organisme : Governement of the principality of Monaco
ID : NA
Organisme : Fondation Flavien
ID : NA
Organisme : GEMLUC

Informations de copyright

© 2023 The Authors; Published by the American Association for Cancer Research.

Auteurs

William Echavidre (W)

Département de Biologie Médicale, Centre Scientifique de Monaco, Monaco, Monaco.

Jérôme Durivault (J)

Département de Biologie Médicale, Centre Scientifique de Monaco, Monaco, Monaco.

Célia Gotorbe (C)

Département de Biologie Médicale, Centre Scientifique de Monaco, Monaco, Monaco.

Thays Blanchard (T)

Département de Biologie Médicale, Centre Scientifique de Monaco, Monaco, Monaco.

Marina Pagnuzzi (M)

Département de Biologie Médicale, Centre Scientifique de Monaco, Monaco, Monaco.

Valérie Vial (V)

Département de Biologie Médicale, Centre Scientifique de Monaco, Monaco, Monaco.

Florian Raes (F)

Université de Grenoble Alpes, INSERM, LRB, Grenoble, France.

Alexis Broisat (A)

Université de Grenoble Alpes, INSERM, LRB, Grenoble, France.

Rémy Villeneuve (R)

Medical Physics Department, Centre Hospitalier Princesse Grace, Monaco, Monaco.

Régis Amblard (R)

Medical Physics Department, Centre Hospitalier Princesse Grace, Monaco, Monaco.

Nicolas Garnier (N)

Medical Physics Department, Centre Hospitalier Princesse Grace, Monaco, Monaco.

Cécile Ortholan (C)

Radiotherapy Department, Centre Hospitalier Princesse Grace, Monaco, Monaco.

Marc Faraggi (M)

Nuclear Medicine Department, Centre Hospitalier Princesse Grace, Monaco, Monaco.

Benjamin Serrano (B)

Medical Physics Department, Centre Hospitalier Princesse Grace, Monaco, Monaco.

Vincent Picco (V)

Département de Biologie Médicale, Centre Scientifique de Monaco, Monaco, Monaco.

Christopher Montemagno (C)

Département de Biologie Médicale, Centre Scientifique de Monaco, Monaco, Monaco.

Classifications MeSH